Smruthi Organics Ltd

Smruthi Organics Ltd., a micro-cap pharmaceuticals and biotechnology company with a market capitalisation of ₹137.00 crores, reported a challenging third quarter for FY2026, with net profit declining 32.04% quarter-on-quarter to ₹1.40 crores from ₹2.06 crores in Q2 FY26. On a year-on-year basis, the company managed a modest 5.41% decline from ₹1.48 crores in Q3 FY25. The stock traded at ₹117.00 on February 13, 2026, down 0.85% from the previous close, reflecting investor concerns over the sequential revenue contraction that has pressured profitability.

Smruthi Organics Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 6 February 2026. This revision reflects a combination of deteriorating technical indicators, subdued long-term financial trends, and valuation concerns despite some recent positive quarterly performance.

Smruthi Organics Ltd has seen its investment rating upgraded from Sell to Hold as of 1 February 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality. This recalibration comes amid a backdrop of mixed long-term performance but recent positive financial results and a shift in technical momentum, prompting a reassessment of the stock’s outlook within the Pharmaceuticals & Biotechnology sector.

Smruthi Organics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 January 2026, providing investors with an up-to-date perspective on its performance and outlook.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s long-term strength.

Smruthi Organics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into its performance and outlook.

Smruthi Organics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Smruthi Organic, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation metrics, reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, providing investors with a clearer perspective on its current standing.

Smruthi Organics, a microcap in the Pharmaceuticals & Biotechnology sector, has recently experienced a score adjustment reflecting changes in its financial metrics. The company reported a profit after tax of Rs 2.06 crore for the quarter ending September 2025, marking significant growth, alongside improvements in operational performance indicators.

Smruthi Organics has reported significant improvements in its financial performance for the quarter ending September 2025, with a notable increase in Profit After Tax and operating profit margin. Despite a low Dividend Per Share, the company has outperformed the Sensex, indicating strong resilience in the market.

Smruthi Organics Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹149.00 crores, reported a concerning performance in Q1 FY26, posting a net loss of ₹1.10 crores compared to a loss of ₹0.92 crores in Q1 FY25. The stock currently trades at ₹129.00, up 1.86% from the previous close, though the company faces mounting operational challenges with revenue declining 30.36% year-on-year to ₹18.99 crores. The quarter's performance marks a significant setback after the company had returned to profitability in the preceding quarters, raising questions about the sustainability of its business model.

Smruthi Organics, a microcap in the Pharmaceuticals & Biotechnology sector, has recently experienced a change in its evaluation. Key technical indicators present a mixed outlook, with some showing bullish momentum while others indicate caution. Financially, the company faces challenges but maintains a low debt-to-equity ratio and attractive valuation.